242 related articles for article (PubMed ID: 18955520)
1. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Yamashita M; Tomozawa T; Kakuta M; Tokumitsu A; Nasu H; Kubo S
Antimicrob Agents Chemother; 2009 Jan; 53(1):186-92. PubMed ID: 18955520
[TBL] [Abstract][Full Text] [Related]
2. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Yamashita M
Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
[TBL] [Abstract][Full Text] [Related]
3. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Kubo S; Tomozawa T; Kakuta M; Tokumitsu A; Yamashita M
Antimicrob Agents Chemother; 2010 Mar; 54(3):1256-64. PubMed ID: 20047917
[TBL] [Abstract][Full Text] [Related]
4. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
8. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Farrukee R; Mosse J; Hurt AC
Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1135-45. PubMed ID: 24093683
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
Honda T; Kubo S; Masuda T; Arai M; Kobayashi Y; Yamashita M
Bioorg Med Chem Lett; 2009 Jun; 19(11):2938-40. PubMed ID: 19414262
[TBL] [Abstract][Full Text] [Related]
10. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
[TBL] [Abstract][Full Text] [Related]
11. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
Aoki FY; Hayden FG
Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
[No Abstract] [Full Text] [Related]
12. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
13. [Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments].
L'vov DK; Burtseva EI; Galegov GA; Beliakova NV; Shevchenko ES; Kolobukhina LV; Merkulova LN; Prilipov AG; Leneva IA; Baranov NI; Gorelikov VN; Abramov DD
Vopr Virusol; 2010; 55(6):10-4. PubMed ID: 21381333
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
[TBL] [Abstract][Full Text] [Related]
16. Antivirals and influenza: frequency of resistance.
Monto AS
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
[TBL] [Abstract][Full Text] [Related]
17. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
18. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
Kubo S; Kakuta M; Yamashita M
Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406
[TBL] [Abstract][Full Text] [Related]
19. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K
N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
